Hereditary Cancer Syndromes > GALNT12, RPS20

NCCN Guidelines



RECOMMEND TESTING FOR ANY PROSTATE CANCER PATIENTS WITH AT LEAST ONE OF THE FOLLOWING:

  • Intraductal histology (tends to be associated with more aggressive disease)

  • Ashkenazi Jewish ancestry

  • 3 or more cancers on the same side of the family (HBOC or Lynch Syndrome type cancers including bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, and/or urothelial cancer)

  • Family history of young (<60) or fatal prostate cancer regardless of pathology or grade

  • T3 or T4 disease

  • Regional or metastatic disease

  • Grade group 4 or 5*

  • PSA > 20ng/ml

 

GENETIC TESTING SHOULD INCLUDE THE FOLLOWING GENES (Consider NGS Panel Testing):
ATM, BRCA1, BRCA2, CHEK2, HOXB13**, MLH1, MSH2, MSH6, PALB2, and PMS2

medical_managment-key.png

CANCER

GENETIC CANCER RISK

Prostate

High Risk

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR GENERAL POPULATIONÂ *

Prostate

Recommend prostate cancer screening.

40 years, or 10 years younger than the earliest prostate cancer diagnosis in the family

Annually, or adjusted based on results from first PSA screen

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

RISK FOR GENERAL POPULATIONÂ *

Prostate

Recommend prostate cancer screening.

40 years, or 10 years younger than the earliest prostate cancer diagnosis in the family

Annually, or adjusted based on results from first PSA screen